Status:
ENROLLING_BY_INVITATION
Population Health Management for KPNC Members With Newly Diagnosed Diabetes: A Randomized Trial of a Proactive and Augmented Initial Care Strategy
Lead Sponsor:
Kaiser Permanente
Collaborating Sponsors:
The Permanente Medical Group
Conditions:
Type 2 Diabetes
Type 2 Diabetes Mellitus (T2DM)
Eligibility:
All Genders
18-74 years
Phase:
NA
Brief Summary
This study is a 2-arm randomized trial of Augmented Initial Type 2 Diabetes (T2D) Care vs. Usual Initial T2D Care among adults (18-74 years) with newly diagnosed T2D who have risk factors (defined by ...
Eligibility Criteria
Inclusion
- Age 18-74 years
- Newly diagnosed with type 2 diabetes
- Kaiser Permanente Northern California member receiving care in a participating service area
- If age ≤45 years, then HbA1c\>8%
- If age\<45 years, then HbA1c\>10%
Exclusion
- Individuals who are pregnant
- Individuals with likely type 1 diabetes (T1D)
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT06906653
Start Date
April 1 2025
End Date
June 1 2027
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente Division of Research
Pleasanton, California, United States, 94588